^
    Back
    Association details:
    Biomarker:ETV6-NTRK3 fusion
    Cancer:Salivary Gland Cancer
    Drug:Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Head Neck
    Title:

    Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series

    Published date:
    03/16/2023
    Excerpt:
    CONTRADICTING EVIDENCE: We describe a multicenter case series of four consecutive patients with ETV6-NTRK3 fusion-positive metastatic salivary secretory carcinoma (SSC) treated with entrectinib….All patients achieved durable radiographic complete response….Durable complete response was achieved with entrectinib in patients with ETV6-NTRK3 fusion-positive metastatic SSC.
    DOI:
    10.1002/hed.27346
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Ann Oncol
    Title:

    What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

    Excerpt:
    While ETV6-NTRK3 was detected in all three tumors (supplementary Figure S2, available at Annals of Oncology online), a novel NTRK3 exon 16 G623R (c.1867G>A) mutation was identified in the M2b tumor, correlating to the development of entrectinib resistance (Figure ​(Figure3B).3B).
    DOI:
    10.1093/annonc/mdw042